HomeNewsMarket

BioCryst Strengthens Rare-Disease Portfolio with USD 700 Million Acquisition of Astria

BioCryst Strengthens Rare-Disease Portfolio with USD 700 Million Acquisition of Astria

BioCryst Pharmaceuticals has announced plans to acquire Astria Therapeutics in a cash-and-stock transaction valued at approximately USD 700 million, further expanding its focus on rare-disease treatments.

Under the terms of the agreement, Astria shareholders will receive USD 8.55 per share in cash along with 0.59 BioCryst shares for each Astria share, representing a premium of about fifty-four percent over Astria’s previous closing price. Astria’s Chief Executive Officer, Jill Milne, is expected to join BioCryst’s board following completion of the acquisition, which is anticipated in the first quarter of 2026.

The deal brings Astria’s lead investigational asset, navenibart, into BioCryst’s pipeline. Navenibart is a long-acting injectable therapy in development for hereditary angioedema (HAE), with data readouts expected in 2027. The acquisition will enable BioCryst to offer both oral and injectable treatment options for HAE, strengthening its market position.

BioCryst currently markets Orladeyo, an oral therapy for HAE, which is projected to generate revenues of between USD 580 million and USD 600 million in 2025. The addition of navenibart broadens BioCryst’s therapeutic offering and reinforces its commitment to innovation in the rare-disease segment.

More news about: market | Published by Darshana | October - 15 - 2025

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members